E Fund Management’s Atara Biotherapeutics ATRA Stock Holding History

E Fund Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,282	Closed	-$93K	–	312
2023 Q1	$93K	Buy	1,282 +228	+22%	+$22.1K	0.01%	323
2022 Q4	$86K	Sell	1,054 -413	-28%	-$43K	0.01%	332
2022 Q3	$139K	Buy	1,467 +442	+43%	+$49.6K	0.01%	319
2022 Q2	$200K	Buy	1,025 +248	+32%	+$40.5K	0.02%	301
2022 Q1	$180K	Buy	+777	New	+$247K	0.01%	303

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E Fund Management's ATRA Position: Q2 2023 in Review

E Fund Management sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 1,282 shares — an estimated $93K sold.

E Fund Management first reported a position in ATRA in Q1 2022 and held it in 5 quarters. The position peaked at $200K in Q2 2022. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

E Fund Management reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
E Fund Management sold 1,282 Atara Biotherapeutics shares in Q2 2023, an estimated $93K.
E Fund Management first reported a position in Atara Biotherapeutics in Q1 2022 and held it in 5 quarters.
E Fund Management's Atara Biotherapeutics position peaked at $200K in Q2 2022.
118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on E Fund Management's 13F filing for Q2 2023, filed 11 Aug 2023.